ArticleFrontiers in oncology2025
Comprehensive analysis of MGLL as a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the molecular landscape of clear cell renal cell carcinoma through integrative transcriptomic analysis and validation using clinical samples.Biochemistry and biophysics reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is a malignancy with significant morbidity and metabolic-related characteristics, necessitating the exploration of novel biomarkers and therapeutic targets. This study focuses on monoglyceride lipase (MGLL), an important molecule identified through RNA sequencing of lipid metabolism-related genes. Methods: We investigated MGLL expression and function in ccRCC by analyzing mRNA data, clinical information, and multiple databases. We used R packages to analyze gene co-expression, immune infiltration, and m7G methylation gene correlations. We constructed a protein-protein interaction (PPI) network and performed prognostic and diagnostic receiver operating characteristic (ROC) curve analyses to identify differentially expressed genes (DEGs). We further validated these genes by qRT-PCR and performed functional experiments by knocking down MGLL using lentiviral vectors. Results: Both qRT-PCR experiments and immunohistochemical data demonstrate that MGLL is upregulated in ccRCC tissues relative to normal tissues. The area under the curve (AUC) values from ROC analyses of three GEO validation datasets (GSE40435, GSE66270, and GSE213324) all exceeded 0.9. The expression of MGLL is associated with poor prognosis and correlates with gender and histological grade. Functional enrichment analysis showed that genes co-expressed with MGLL were mainly involved in proteasome-mediated protein degradation, macroautophagy, and the response to endoplasmic reticulum stress. MGLL expression is significantly positively correlated with the infiltration of neutrophils, Th17 cells, eosinophils, and dendritic cells. In contrast, it is significantly negatively correlated with cytotoxic T cells, NK CD56bright cells, and CD8 T cells. The PPI network and the correlation analysis between MGLL and m7G genes identified a total of 23 DEGs. Additionally, prognostic LASSO regression coefficients combined with ROC analysis reveal that ACLY, CALM3, NSUN2, NUDT16, NUDT4, and PKM have potential prognostic and diagnostic value. qRT-PCR experiments confirmed the expression of 13 genes from the prognostic LASSO model in ccRCC cell lines ACHN, A498, and 786-O, as well as in normal renal tubular epithelial cells HK-2. Inhibition of MGLL expression reduced ccRCC cell proliferation, colony formation, and migration. Conclusion: This investigation elucidates the diagnostic and prognostic significance of MGLL in ccRCC, while offering mechanistic insights into its biological functions and potential therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.